Neuro-Oncology

Top Story

Radiosurgery alone lessens cognitive decline for patients with limited brain metastases

July 26, 2016

The use of stereotactic radiosurgery without adjuvant whole-brain radiation lessened cognitive deterioration at 3 months among patients with one to three brain metastases, according to the results of multicenter, randomized trial.

However, OS did not differ between patients who received stereotactic radiosurgery (SRS) alone or with whole-brain radiotherapy (WBRT).

Second malignancies, death common among cancer survivors

July 25, 2016
Approximately one in 12 patients with a common primary tumor were diagnosed with a second primary malignancy between 1992 and 2008, according to results of a SEER…

Delirium frequently underdiagnosed in patients with advanced cancers

July 25, 2016
Delirium occurs frequently but appears underdiagnosed in patients with advanced cancer who presented in the ED, according to the results of a randomized observational…
At Issue

Immune checkpoint inhibitors show promise in brain tumors, questions remain

July 20, 2016
The promise of immune checkpoint inhibitors in systemic cancers such as melanoma, non-small-cell lung cancer and breast cancer has prompted researchers to start…
CME

The Patient with Severe Leukocytosis

No commercial support for this activity.

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML)…
More »
Video
Meeting News Coverage

VIDEO: Liquid biopsy technology a ‘major advance’ but still requires validation

May 5, 2016
More »
Featured
2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

CME

The Patient with Lymphadenopathy

No commercial support for this activity.

Castleman’s disease is a rare lymphoproliferative disorder that is characterized by enlargement of 1 (unicentric) or…
More »

Radiosurgery alone lessens cognitive decline for patients with limited brain metastases

July 26, 2016
The use of stereotactic radiosurgery without adjuvant whole-brain radiation lessened cognitive deterioration at 3 months among patients with one to…

Second malignancies, death common among cancer survivors

July 25, 2016
Approximately one in 12 patients with a common primary tumor were diagnosed with a second primary malignancy between 1992 and 2008, according to…

Delirium frequently underdiagnosed in patients with advanced cancers

July 25, 2016
Delirium occurs frequently but appears underdiagnosed in patients with advanced cancer who presented in the ED, according to the results of a…

At Issue

Immune checkpoint inhibitors show promise in brain tumors, questions remain

July 20, 2016
The promise of immune checkpoint inhibitors in systemic cancers such as melanoma, non-small-cell lung cancer and breast cancer has prompted…

At IssueVideo

VIDEO: Novel immune checkpoint blockade, vaccine-based therapies show promise in glioblastoma

July 19, 2016
Novel therapies are beginning to refute the dogma that immune therapy does not work in patients with primary brain tumors, according to Manmeet

In the Journals

Hispanic, younger children underrepresented in pediatric oncology trials

July 18, 2016
Underrepresentation of Hispanic patients and children aged 0 to 4 years occurred frequently in phase 1 trials, according to a meta-analysis of trials…

Memorial Sloan Kettering program designed to meet needs of teens, young adults with cancer

July 13, 2016
Memorial Sloan Kettering Cancer Center launched a new initiative designed to help teens and young adults with cancer. The program offers services to…

In the Journals

Childhood cancer survivors at risk for endocrine disorders

July 12, 2016
The risk for endocrinopathies increased substantially over time among childhood cancer survivors, especially among those who received high-risk…

FDA News

FDA grants rare pediatric disease designation to ABT-414 for DIPG

July 12, 2016
The FDA granted rare pediatric disease designation to ABT-414 for the treatment of children with epidermal growth factor receptor–amplified…

In the Journals

Cancer center advertising expenditures more than triple since 2005

July 11, 2016
Cancer treatment centers in the United States spent $173 million on advertising in the year 2014, according to a research letter published in JAMA

More Headlines »
morganatic-roan